Cerebrolysin for vascular dementia

Ning Chen1, Mi Yang, Jian Guo

  • 1Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.

Insights

Cerebrolysin may improve cognitive and global function in vascular dementia patients. However, more research is needed due to limited trials and short follow-up periods for routine treatment recommendations.

Area of Science:

  • Neurology
  • Clinical Pharmacology

Background:

  • Vascular dementia is a prevalent neurological disorder lacking definitive treatments.
  • Cerebrolysin shows potential for neurotrophic and pro-cognitive effects, but existing studies have inconsistent findings.

Purpose of the Study:

  • To evaluate the efficacy and safety of Cerebrolysin for treating vascular dementia.
  • To synthesize evidence from randomized controlled trials on Cerebrolysin's impact on cognitive and global function.

Main Methods:

  • A systematic search of the ALOIS database was conducted for randomized controlled trials (RCTs) of Cerebrolysin in vascular dementia.
  • Six RCTs involving 597 participants were included after independent selection and quality assessment by two authors.
  • Data extraction and meta-analysis were performed to assess treatment effects and adverse events.

Main Results:

  • Meta-analyses indicated beneficial effects of Cerebrolysin on general cognitive function (MMSE, ADAS-cog+) and global clinical function (response rates).
  • No significant difference in the occurrence of non-serious adverse events was observed between Cerebrolysin and control groups.
  • The observed effects suggest potential benefits for patients with mild to moderate vascular dementia.

Conclusions:

  • Cerebrolysin may positively influence cognitive and global function in mild to moderate vascular dementia.
  • Insufficient evidence currently supports Cerebrolysin's routine use due to limited trials, variable treatment durations, and short follow-up periods.
  • Further high-quality, long-term studies are warranted to establish Cerebrolysin's role in vascular dementia management.
Abstract

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Cerebral Edema l: Introduction01:19

Cerebral Edema l: Introduction

Cerebral edema is a pathological increase in brain water content that disrupts intracranial pressure regulation and impairs neurological function. Because the cranial vault is rigid, even modest increases in tissue volume can compromise cerebral perfusion, distort neural structures, and initiate secondary injury. Cerebral edema develops through four principal mechanisms: vasogenic, cytotoxic, interstitial, and ionic.Vasogenic EdemaVasogenic edema arises from disruption of the blood–brain...
Hemorrhagic Stroke l: Introduction01:17

Hemorrhagic Stroke l: Introduction

A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.